✅   Editas sells future CRISPR license fees; Plus, news about Oncolytics Biotech

tech

Editas sells future CRISPR licensing fees from Vertex: DRI Healthcare Trust is paying $57 million upfront to the gene editing company in exchange for future licensing payments from Vertex, which struck an agreement with Editas to use its CRISPR/Cas9 gene editing for its sickle cell and beta thalassemia therapy Casgevy. DRI will get between $5 million and $40 million a year, plus a “mid-double-digit percentage” of Editas’ portion of a $50 million payment that it may get from Vertex. (Some of the licensing payments also go to the Broad Institute and Harvard.) Editas’ stock $EDIT was up about 4% on Friday morning.

Endpoints     Oct 04, 2024